Evidence map›Paper›PMID 42522424›Full record

ArticleFuture oncology (London, England)2026

Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Arun A Azad, Bhavik J Pandya, Hemant Singh Bhadauria, Erhan Berrak, Vagia Daki, Paulo Martins, Janet Kim, Alexis Serikoff, Gianluca Baio, Andrew J Armstrong

Registry-linked trialAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02677896 (A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02677896 phase3completednot on this map

A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

TypeinterventionalSponsorAstellas Pharma Global Development, Inc.Ran2016 to 2024Enrolled1,150ConditionsMetastatic Hormone Sensitive Prostate CancerArmsEnzalutamide, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arun A AzadDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Bhavik J PandyaMedical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA.
Hemant Singh BhadauriaMedical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA.
Erhan BerrakMedical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA.
Vagia DakiEMEA Real World Methods and Evidence Generation, IQVIA, Athens, Greece.
Paulo MartinsEMEA Real World Methods and Evidence Generation, IQVIA, Lisbon, Portugal.
Janet KimMedical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA.
Alexis SerikoffMedical Affairs, Astellas Pharma Global Inc., Northbrook, IL, USA.
Gianluca BaioDepartment of Statistical Science, University College London, London, UK.
Andrew J ArmstrongCenter for Prostate & Urologic Cancers, Duke Cancer Institute, Durham, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus apalutamide + ADT in metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC). PATIENTS AND

methodsIndividual patient data from patients with ≥1 confirmed bone metastasis in ARCHES (NCT02677896; enzalutamide + ADT vs placebo + ADT;

resultsThis MAIC suggested similar estimated efficacy between enzalutamide and apalutamide for OS (HR: 0.81, 95% confidence interval [CI]: 0.58-1.15) and TTPP (HR: 0.65, 95% CI: 0.41-1.03). Patients treated with enzalutamide + ADT had improved rPFS versus those treated with apalutamide + ADT (HR: 0.66, 95% CI: 0.45-0.98), but differences were not significant in sensitivity analyses aligning assessment methods.

conclusionsThis analysis suggested broadly similar efficacy between enzalutamide and apalutamide in patients with mHSPC. Findings should be interpreted in the context of inherent MAIC limitations.

Indexed as

Androgen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsPhenylthiohydantoinProstatic NeoplasmsThiohydantoinsAgedAged, 80 and overBenzamidesClinical Trials, Phase III as TopicHumansMaleMiddle AgedNitrilesProgression-Free SurvivalProstate-Specific AntigenAndrogen AntagonistsapalutamideBenzamidesenzalutamideNitrilesPhenylthiohydantoinProstate-Specific AntigenThiohydantoinsApalutamideenzalutamidematching-adjusted indirect comparisonmHSPCoverall survivalprogression-free survival

Identifiers

PMID42522424
PMCPMC13540096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.